



ASX/MEDIA RELEASE

5 April 2018

## Dispatch of Scheme Booklet to Shareholders and Variation of Proposed Implementation Date

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) (**Sirtex**) today announces the dispatch of the scheme booklet (**Scheme Booklet**) and personalised proxy forms to shareholders in relation to the proposed acquisition of all of the shares in Sirtex by Varian Medical Systems Australasia Holdings Pty Ltd, a wholly-owned subsidiary of Varian Medical Systems, Inc. (**Varian**), by way of scheme of arrangement (**Scheme**). Shareholders who have elected to receive communications electronically have been sent an email with links to where they can download the Scheme Booklet and proxy form while other shareholders have been mailed a printed copy of the Scheme Booklet.

A copy of the Scheme Booklet was lodged with the ASX on 29 March 2018 and is available on Sirtex's website at [www.sirtex.com](http://www.sirtex.com).

All Sirtex shareholders are encouraged to read the Scheme Booklet in its entirety before deciding whether or not to vote in favour of the Scheme. Shareholders can vote either by attending the scheme meeting (**Scheme Meeting**) in person, or by lodging a proxy form with the Sirtex share registry by 10:00am (Sydney time) on Saturday, 5 May 2018. Any proxy forms received after that time will not be valid for the scheduled Scheme Meeting. Details of how to lodge the proxy form are included in the Scheme Booklet.

The Scheme Meeting will be held at 10:00am (Sydney time) on Monday, 7 May 2018 at the Royal Automobile Club of Australia, 89 Macquarie Street, Sydney NSW 2000.

If shareholders approve the Scheme at the Scheme Meeting and it is subsequently approved by the Federal Court of Australia, the Scheme will be implemented on the implementation date. In the Scheme Booklet, the proposed implementation date was stated to be Monday, 28 May 2018 however Sirtex advises that this has now been changed to be Friday, 25 May 2018 (Sydney time). Accordingly, references in the Scheme Booklet to 28 May 2018 should be read as references to 25 May 2018. This revised date remains subject to change and may be varied by Sirtex. Any further changes will be announced by Sirtex on ASX. This change does not affect any of the other dates relating to the Scheme as outlined in the Scheme Booklet.

If after reading the Scheme Booklet you have any further questions in relation to the Scheme or the Scheme Booklet, please contact the Sirtex Shareholder Information Line on 1300 794 682 (within Australia) or +61 1300 794 682 (outside Australia) Monday to Friday from 8:30am to 5:30pm (Sydney time).

– ENDS –

---

**Head Office**  
Level 33, 101 Miller Street  
North Sydney, NSW 2060  
Australia

**Americas**  
300 Unicorn Park Drive  
Woburn, MA 01801  
United States

**Europe, Middle East & Africa**  
Josef-Schumpeter-Allee 33  
53227 Bonn  
Germany

**Asia Pacific**  
50 Science Park Road, #01-01  
The Kendall Science Park II  
Singapore 117406

## **About Sirtex Medical, [www.sirtex.com](http://www.sirtex.com)**

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

### **Investor Enquiries:**

Mr Andrew McLean  
CEO  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8400

### **Investor/Media Enquiries:**

Dr Tom Duthy  
Global Head of Investor Relations &  
Corporate Development  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8427  
Email: [tduthy@sirtex.com](mailto:tduthy@sirtex.com)

To subscribe to our email alert service for ASX Announcements, please visit:  
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**  
Visit us on LinkedIn: **Sirtex Medical Limited**